BNTX Stock Price, Chart, Stats & News
BNTX chart
Fundamentals
Gross margin | 77.68% |
Operating margin | -45.88% |
Pretax margin | -36.65% |
Net margin | -39.60% |
Effective tax rate | -8.06% |
ROA | -5.16% |
ROE | -6.03% |
D/E | 0.01x |
Interest coverage ratio | -80.27x |
BNTX valuation
P/E | – |
P/S | 6.52x |
P/B | 0.95x |
P/CF | 39.21x |
P/FCF | 67.46x |
P/OCF | 39.21x |
PEG | 0.19x |
EV multiple | -41.05x |
About
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors.
Similar securities
Based on sector and market capitalization
